The government's move toward a fair-equals-cheap model of drug pricing may have long-term implications for patients and our health-care system.
The prime minister and his health minister, Ginette Petitpas Taylor, pictured speaking to reporters Dec. 5 in the House foyer after Question Period, ought to reconsider their recent stance on drug pricing, writes Life Sciences Ontario chief Jason Field. The Hill Times photograph by Andrew Meade
Earlier this month, the Patented Medicine Prices Review Board published new regulations that could see drug prices cut by up to 20 per cent.
People. Policy. Politics. This is an exclusive subscriber-only story.
What is and isn’t considered a subsidy is politically charged. The government and industry are both likely to dispute or take issue with the inclusion of some, or many, of the programs to the group's tally.
New prescribed policies, procedures forced people to think about how they were acting, creating a 'profound' change in terms of staff understanding how they need to relate in the workplace, says the PMO's Marci Surkes.